OBJECTIVE: We compared the IHC expression of MYB in solid-variant adenoid cystic carcinoma with that in other triple-negative breast cancers.
METHODS: We conducted IHC staining of 210 samples of triple-negative breast cancers, including solid-variant adenoid cystic carcinoma (n = 17), metaplastic breast carcinoma (n = 44), basaloid triple-negative breast cancer (n = 21), and other triple-negative invasive ductal carcinoma (n = 128). We classified nuclear staining of MYB as diffuse/strong (3+), focal moderate (2+), focal weak (1+), or none (0).
RESULTS: All 17 solid/basaloid adenoid cystic carcinoma cases exhibited 3+ MYB expression. Of the 21 solid/basaloid triple-negative breast cancers, one (5%) had 2+ expression, seven (33%) 1+ expression, and 13 (62%) 0 expression. Of the 44 metaplastic carcinoma cases, 39 cases (89%) had no (0) staining, and the other five cases had focal weak (1+) or moderate (2+) staining. Among the 128 triple-negative invasive ductal carcinoma cases, 92 cases (72%) had no (0) staining, 36 cases (28%) exhibited focal weak (1+) or moderate (2+) staining.
CONCLUSIONS: Our study revealed diffuse/strong MYB staining (3+) only in solid/basaloid adenoid cystic carcinomas. Thus, we recommend routine MYB IHC staining in triple-negative breast carcinoma with solid/basaloid morphology to improve diagnostic accuracy.
目的:我们比较了实体变异型腺样囊性癌与其他三阴性乳腺癌中MYB的IHC表达。
方法:我们对210例三阴性乳腺癌样本进行了IHC染色,包括实性变异型腺样囊性癌(n=17),化生性乳腺癌(n=44),基底细胞样三阴性乳腺癌(n=21),和其他三阴性浸润性导管癌(n=128)。我们将MYB的核染色分类为弥漫性/强(3+),局灶性中度(2+),局灶弱(1+),或无(0)。
结果:17例实性/基底样腺样囊性癌均有3+MYB表达。在21种实体/基底细胞样三阴性乳腺癌中,一个(5%)有2+表达,七个(33%)1+表达,表达13(62%)0。44例化生性癌,39例(89%)无(0)染色,其余5例有局灶性弱(1+)或中度(2+)染色。在128例三阴性浸润性导管癌患者中,92例(72%)无(0)染色,36例(28%)显示局灶性弱(1)或中度(2)染色。
结论:我们的研究仅在实性/基底样腺样囊性癌中显示弥漫性/强MYB染色(3+)。因此,我们建议对具有实性/基底样形态的三阴性乳腺癌进行常规MYBIHC染色,以提高诊断准确性.